Brain Cancer - Market Insights, Epidemiology and Market Forecast– 2030

Brain Cancer - Market Insights, Epidemiology and Market Forecast– 2030

  • January 2021 •
  • 298 pages •
  • Report ID: 6025266 •
  • Format: PDF
‘Brain Cancer - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Brain Cancer, historical and forecasted epidemiology as well as the Brain Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Brain Cancer market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Brain Cancer market size from 2018 to 2030. The report also covers current Brain Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2018–2030
Brain Cancer Disease Understanding and Treatment Algorithm

Brain Cancer Overview
A brain tumor, known as an intracranial tumor, central nervous system (CNS) tumors represent a group of diseases that have in common the abnormal development of mass lesions in the brain, spinal cord or its coverings. A brain tumor can be classified into two main groups, i.e. primary and metastatic. A primary brain tumor is often described as “low grade” or “high grade.” A low-grade tumor generally grows slowly, but it can turn into a high-grade tumor, whereas a high-grade tumor is more likely to grow faster. Secondary brain tumors, also called brain metastases, are much more common than primary tumors in adults. The most common types of primary tumors in adults are meningiomas and astrocytomas, such as glioblastomas. In children, the most common types of brain tumors include medulloblastomas, low-grade astrocytomas (pilocytic), ependymomas, craniopharyngiomas, and brainstem gliomas. All types of brain tumors produce symptoms that vary depending on the part of the brain involved. These symptoms may include headaches, seizures, problems with vision, vomiting and mental changes. Even though the exact cause of most brain tumors is unknown, some uncommon risk factors include exposure to chemicals, radiation, and family history of brain tumors.

Brain Cancer Diagnosis
Most brain tumors are not diagnosed until after symptoms appear. In general, diagnosing a brain tumor usually begins with magnetic resonance imaging (MRI). Once MRI shows a tumor in the brain, the most common way to determine the type of brain tumor is to look at the results from a tissue sample after a biopsy or surgery. Blood tests are also done to help diagnose certain brain tumors such as pituitary gland, pineal region and germ cell tumors.
Sophisticated imaging techniques are used to pinpoint brain tumors. Diagnostic tools used for this purpose include computed tomography (CT or CAT scan) and MRI. Other MRI sequences can help the surgeon plan the resection of the tumor based on the location of the normal nerve pathways of the brain. Intraoperative MRI is also used during surgery to guide tissue biopsies and tumor removal. Magnetic resonance spectroscopy (MRS) is used to examine the tumor’s chemical profile and determine the nature of the lesions seen on the MRI. Positron emission tomography (PET scan) can help detect recurring brain tumors.

Brain Cancer Treatment
Treatment options for brain cancers include surgery, radiation therapy, chemotherapy, and targeted therapy. The treatment options and recommendations depend on several factors like the size, type, and grade of the tumor, whether the tumor is putting pressure on vital parts of the brain, if the tumor has spread to other parts of the CNS or the body, the possible side effects and finally, the treatment preferences and overall health of the patient.
For a low-grade brain tumor, surgery may be the only treatment needed, especially if all of the tumor can be removed. If there is visible tumor remaining after surgery, radiation therapy and chemotherapy may be used. For higher-grade tumors, treatment usually begins with surgery, followed by radiation therapy and chemotherapy.

Brain Cancer Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incidence of Primary Brain Tumors, Grade-specific Incidence of Brain Tumors, Type-specific Incidence of Brain Tumors, Gender-specific Incidence of Brain Tumors, and Age-specific Incidence of Brain Tumors in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.

Key Findings
This section provides glimpse of the Brain Cancer epidemiology in the 7MM.
• The total incident population of Primary Brain Tumors in the seven major markets was estimated to be 60,246 in 2020. In case of Primary Brain Tumors patients in the United States, the incident cases were 23,056 in 2020.
• The total incident population of Primary Brain Tumors in the 7MM is expected to increase at a CAGR of 0.96% during the forecast period 2021–2030.
• Brain Tumors can be divided into, Low-grade (I and II) and High-grade (III and IV) tumors. In the United States, these cases were 6,917 and 16,139, respectively, in 2020.
• In the United States, the incidence of Brain Tumors was 13,534 in males and 9,522 in females, in 2020.
• There are many types of Brain Tumors; however, the types that are considered in this report include Pilocytic Astrocytoma, Diffuse Astrocytoma, Anaplastic Astrocytoma, Oligodendrogliomas, Glioblastoma Multiforme (GBM), Diffuse midline glioma (Earlier called as DIPG), and others, which represented 1,383, 3,458, 1,844, 1,614, 11,989, 853, and 1,914 cases, respectively, in the United States, in 2020.
• In the United States, the highest incidence of Brain Tumors was in the age-group 40–64 years with 10,144 cases, followed by the age-group ?65 years with 8,992 cases in 2020. The lowest incidence of Brain Tumors was reorted in the age-group 0–39 years with 3,919 cases in 2020.
• In the EU5 countries, the incident population of Primary Brain Tumors was maximum in Italy with 7,320 cases, followed by the Germany with 7,173 cases in 2020. While, the United Kingdom accounted for the lowest incident population of the indication with 4,433 cases in 2020.
• As per the analysis, Japan had 8,275 incident cases of Primary Brain Tumors in 2020.

Country Wise- Brain Cancer Epidemiology
The epidemiology segment also provides the Brain Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Brain Cancer Drug Chapters
The drug chapter segment of the Brain Cancer report encloses the detailed analysis of Brain Cancer marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Brain Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Brain Cancer Marketed Drugs 
Avastin: Genentech 
Avastin (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps in reducing the activity of VEGF and regressing the vascularization of tumors, which normalizes the tumor vasculature and inhibits the formation of new tumor vasculature, thereby preventing the tumor growth. VEGF is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. Avastin is indicated for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent. 
Product details in the report… 
Temodar/Temodal: Merck 
The active pharmaceutical ingredient in Temodar/Temodal, is an imidazotetrazine derivative of the alkylating agent dacarbazine, used for the treatment of newly diagnosed glioblastoma multiforme and refractory anaplastic astrocytoma. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. Temozolomide targets selectively tumoral tissues; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity, and it is eliminated rapidly. Temodar/Temodal was initially commercialized by Merck in the different countries, whereas Baxter Oncology was responsible for the manufacture of Temodar injection. However, due to patent expiry, the market holds the generic version of the drug. Recently, the gel formulation of Temozolomide has also been approved by Double Bond Pharmaceuticals. 
Product details in the report…